Xeris Biopharma (NASDAQ:XERS) and Aptorum Group (NASDAQ:APM) Head to Head Analysis

Aptorum Group (NASDAQ:APM) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Earnings & Valuation

This table compares Aptorum Group and Xeris Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430,000.00	11.52	-$1.36 million	N/A	N/A
Xeris Biopharma	$291.85 million	4.49	$550,000.00	$0.06	126.42

Xeris Biopharma has higher revenue and earnings than Aptorum Group.

Insider & Institutional Ownership

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Aptorum Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares Aptorum Group and Xeris Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Xeris Biopharma	3.81%	735.00%	3.24%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Aptorum Group and Xeris Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1	0	0	0	1.00
Xeris Biopharma	1	2	4	0	2.43

Xeris Biopharma has a consensus price target of $10.80, indicating a potential upside of 42.39%. Given Xeris Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Aptorum Group.

Summary

Xeris Biopharma beats Aptorum Group on 10 of the 12 factors compared between the two stocks.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.